Letitia Lensun
UCB Pharma (United Kingdom)(GB)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Protein Kinase Regulation and GTPase Signaling, Biochemical and Molecular Research, Chronic Lymphocytic Leukemia Research, Cell death mechanisms and regulation
Most-Cited Works
- → The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer(2008)741 cited
- → Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941(2009)271 cited
- → GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway(2011)227 cited
- → Functional characterization of a novel somatic oncogenic mutation of PIK3CB(2017)44 cited
- → Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma(2021)8 cited
- → 217 POSTER Pre-clinical evaluation of efficacy and PK/PD biomarkers of GDC-0941, a potent class 1 PI3K inhibitor(2008)2 cited
- → Data from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941(2023)
- → Supplementary Figure 3B from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941(2023)
- → Data from GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway(2023)